Analysts predict that Clorox Co (NYSE:CLX) will post sales of $1.48 billion for the current quarter, according to Zacks. Five analysts have issued estimates for Clorox’s earnings, with estimates ranging from $1.47 billion to $1.49 billion. Clorox reported sales of $1.42 billion during the same quarter last year, which would suggest a positive year-over-year growth rate of 4.2%. The company is expected to announce its next earnings results on Friday, February 1st.

According to Zacks, analysts expect that Clorox will report full-year sales of $6.33 billion for the current year, with estimates ranging from $6.28 billion to $6.36 billion. For the next fiscal year, analysts anticipate that the company will report sales of $6.50 billion, with estimates ranging from $6.45 billion to $6.57 billion. Zacks’ sales calculations are an average based on a survey of analysts that follow Clorox.

Clorox (NYSE:CLX) last issued its quarterly earnings results on Wednesday, October 31st. The company reported $1.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.59 by $0.03. The business had revenue of $1.56 billion during the quarter, compared to analysts’ expectations of $1.53 billion. Clorox had a return on equity of 102.65% and a net margin of 13.59%. The firm’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period in the previous year, the company posted $1.46 earnings per share.

Several equities research analysts have weighed in on CLX shares. Zacks Investment Research upgraded Clorox from a “hold” rating to a “buy” rating and set a $171.00 target price for the company in a research note on Wednesday, October 3rd. Argus upgraded Clorox from a “hold” rating to a “buy” rating and set a $175.00 target price for the company in a research note on Tuesday, September 25th. ValuEngine upgraded Clorox from a “hold” rating to a “buy” rating in a research note on Saturday, September 22nd. BMO Capital Markets restated a “buy” rating and set a $153.00 target price on shares of Clorox in a research note on Friday, August 3rd. Finally, Barclays set a $131.00 target price on Clorox and gave the stock a “hold” rating in a research note on Saturday, October 6th. Four analysts have rated the stock with a sell rating, eight have given a hold rating and three have assigned a buy rating to the company’s stock. Clorox presently has a consensus rating of “Hold” and a consensus target price of $141.64.

Shares of CLX stock traded up $0.37 during trading on Wednesday, hitting $162.39. The company had a trading volume of 565,000 shares, compared to its average volume of 1,193,185. The company has a current ratio of 1.07, a quick ratio of 0.65 and a debt-to-equity ratio of 3.38. The stock has a market cap of $20.68 billion, a P/E ratio of 25.94, a price-to-earnings-growth ratio of 3.98 and a beta of 0.28. Clorox has a one year low of $113.57 and a one year high of $163.44.

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 8th. Shareholders of record on Wednesday, January 23rd will be paid a dividend of $0.96 per share. This represents a $3.84 annualized dividend and a yield of 2.36%. The ex-dividend date is Tuesday, January 22nd. Clorox’s payout ratio is presently 61.34%.

In other news, COO Dawn C. Willoughby sold 3,387 shares of the company’s stock in a transaction on Wednesday, September 5th. The shares were sold at an average price of $148.01, for a total transaction of $501,309.87. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Michael R. Costello sold 6,882 shares of the company’s stock in a transaction on Thursday, November 15th. The stock was sold at an average price of $160.08, for a total transaction of $1,101,670.56. The disclosure for this sale can be found here. Insiders have sold 93,970 shares of company stock valued at $14,567,178 over the last 90 days. Corporate insiders own 1.40% of the company’s stock.

Large investors have recently made changes to their positions in the company. Berkshire Asset Management LLC PA increased its holdings in shares of Clorox by 17.6% during the third quarter. Berkshire Asset Management LLC PA now owns 3,119 shares of the company’s stock worth $469,000 after buying an additional 467 shares in the last quarter. Carillon Tower Advisers Inc. increased its holdings in shares of Clorox by 82.8% during the second quarter. Carillon Tower Advisers Inc. now owns 109,150 shares of the company’s stock worth $14,763,000 after buying an additional 49,450 shares in the last quarter. Legacy Advisors LLC acquired a new position in shares of Clorox during the third quarter worth $150,000. Victory Capital Management Inc. increased its holdings in shares of Clorox by 0.4% during the second quarter. Victory Capital Management Inc. now owns 105,329 shares of the company’s stock worth $14,246,000 after buying an additional 456 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. increased its holdings in shares of Clorox by 7.2% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 63,730 shares of the company’s stock worth $8,620,000 after buying an additional 4,281 shares in the last quarter. Institutional investors own 76.33% of the company’s stock.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.

Further Reading: What are earnings reports?

Get a free copy of the Zacks research report on Clorox (CLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.